Sigma-Aldrich Anti-Bnip3L Clone 2N10-H2 Zoomab Rb

BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like (UniProt: O60238; also known as Adenovirus E1B19K-binding protein B5, BCL2/adenovirus E1B 19 kDa protein-interacting protein 3A, NIP3-like protein X (NIP3L)) is encoded by the BNIP3L (also known as BNIP3A, BNIP3H, NIX) gene (Gene ID: ) in human. BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like (BNIP3L) is a pro-apoptotic member of the Bcl-2 protein family characterized by a BH3 domain, crucial for its interaction with other Bcl-2 family proteins. BNIP3L is a mitochondrial protein that plays a significant role in the induction of apoptosis and autophagy. It is involved in the regulation of mitochondrial dynamics and quality control by mediating mitophagy, a process essential for the removal of damaged mitochondria. BNIP3L is ubiquitously expressed, with high levels in the heart and skeletal muscle, and is primarily localized to the outer mitochondrial membrane. The protein′s expression is upregulated under hypoxic conditions, where it is regulated by hypoxia-inducible factors (HIFs), linking it to cellular responses to low oxygen levels. BNIP3L has been implicated in cancer, where its expression can influence tumor progression and metastasis. BNIP3L expression is often altered in various cancers, including breast and pancreatic cancers, where it can function as a tumor suppressor by promoting cell death, thus influencing tumor progression and metastasis. This ZooMAb^® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Vasagiri, N. and Kutala, V.K., (2014), Mol Biol Rep, 41(11), 7705-14; Macher-Goeppinger, S., et Al., (2017), Transl Oncol, 10(6), 869-875; Imazu, T., et Al., (1999), Oncogene, 18(32), 4523-9)

We are committed to bringing you greener alternative products, which adhere to one or more of the 12 Principles of Green Chemistry. This antibody is preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed, and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

KLH-conjugated linear peptide corresponding to 25 amino acids from the C-terminal half of human BNIP3L.

Quality Control Testing

Evaluated by Western Blotting in SH-SY5Y cell lysate.

Western Blotting Analysis: A 1:10,000 dilution of this antibody detected BNIP3L in SH-SY5Y cell lysate.

Tested Applications

Western Blotting Analysis: A 1:10,000 dilution from a representative lot detected BNIP3L in HepG2 and C2C12 cell lysate.

Affinity Binding Assay: A representative lot of this antibody bound with BNIP3L peptide with at least ten thousand-fold (10,000X) higher affinity than with non-specific control peptide.

Immunohistochemistry (Paraffin) Analysis: A 1:1,000 dilution from a representative lot detected BNIP3L in human kidney tissue sections.

Immunocytochemistry Analysis (ICC): A 1:100 dilution from a representative lot detected BNIP3L in HepG2 cells.

Clone 2N10-H2 is a ZooMAb^® rabbit recombinant monoclonal antibody that detects BNIP3L. It targets an epitope within 25 amino acids from the C-terminal half.

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.